Quantcast
Home > Quotes > ALBO

Albireo Pharma, Inc. Common Stock (ALBO) Quote & Summary Data

ALBO 
$31.69
*  
0.31
0.97%
Get ALBO Alerts
*Delayed - data as of Jun. 20, 2019 13:15 ET  -  Find a broker to begin trading ALBO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ALBO Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 31.44 / $ 31.69
1 Year Target
62
Today's High / Low
$ 32.54 / $ 31.45
Share Volume
6,262
50 Day Avg. Daily Volume
60,664
Previous Close
$ 32
52 Week High / Low
$ 38.69 / $ 19.1033
Market Cap
381,525,575
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.81

Intraday Chart

Shares Traded

Share Volume:
6,262
50 Day Avg. Daily Volume:
60,664

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -5.12

Trading Range

The current last sale of $31.69 is 65.89% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 32.54 $ 38.69
 Low: $ 31.45 $ 19.1033

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal, or GI, diseases and disorders. The initial target indication for our lead product candidate, A4250, is progressive familial intrahepatic cholestasis, or PFIC, a rare, life-threatening genetic disorder affecting young children for which there is currently no approved drug treatment. We completed a Phase 2 clinical trial of A4250 in children with chronic cholestasis and pruritus, and in May of 2018 we enrolled the first patient in our Phase 3 clinical trial for A4250 in patients with PFIC, which we refer to as PEDFIC 1. In June of 2018, the FDA granted a rare pediatric disease designation to A4250 for the treatment of PFIC, which affirms our eligibility to apply for a rare pediatric disease priority review voucher upon submission of a new drug application for A4250.  ... More ...  



Risk Grade

Where does ALBO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 32.54
Open Date:
Jun. 20, 2019
Close Price:
$ 32
Close Date:
Jun. 19, 2019


Consensus Recommendation

Analyst Info